These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 15385814

  • 1. Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction.
    Cai J, Terasaki PI, Bloom DD, Torrealba JR, Friedl A, Sollinger HW, Knechtle SJ.
    Transplantation; 2004 Sep 27; 78(6):919-24. PubMed ID: 15385814
    [Abstract] [Full Text] [Related]

  • 2. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring.
    Knechtle SJ, Pascual J, Bloom DD, Torrealba JR, Jankowska-Gan E, Burlingham WJ, Kwun J, Colvin RB, Seyfert-Margolis V, Bourcier K, Sollinger HW.
    Am J Transplant; 2009 May 27; 9(5):1087-98. PubMed ID: 19344431
    [Abstract] [Full Text] [Related]

  • 3. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
    Muñoz AS, Cabanayan-Casasola CB, Danguilan RA, Padua FB, Ona ET.
    Transplant Proc; 2008 Sep 27; 40(7):2230-3. PubMed ID: 18790200
    [Abstract] [Full Text] [Related]

  • 4. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation.
    Barth RN, Janus CA, Lillesand CA, Radke NA, Pirsch JD, Becker BN, Fernandez LA, Thomas Chin L, Becker YT, Odorico JS, D'Alessandro AM, Sollinger HW, Knechtle SJ.
    Transpl Int; 2006 Nov 27; 19(11):885-92. PubMed ID: 17018123
    [Abstract] [Full Text] [Related]

  • 5. Influence of HLA disparity, immunosuppressive regimen used, and type of kidney allograft on production of anti-HLA class-I antibodies after transplant and occurrence of rejection.
    Abdelnoor AM, Ajib R, Chakhtoura M, Daouk M, Medawar W, Uwaydah M, Sawah SI, Khauli RB.
    Immunopharmacol Immunotoxicol; 2009 Nov 27; 31(1):83-7. PubMed ID: 18752168
    [Abstract] [Full Text] [Related]

  • 6. Campath-1H use in pediatric renal transplantation.
    Bartosh SM, Knechtle SJ, Sollinger HW.
    Am J Transplant; 2005 Jun 27; 5(6):1569-73. PubMed ID: 15888071
    [Abstract] [Full Text] [Related]

  • 7. The use of Campath-1H as induction therapy in renal transplantation: preliminary results.
    Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roohipour R, Carreno MR, Roth D, Ruiz P, Kupin W, Rosen A, Esquenazi V, Tzakis AG, Miller J.
    Transplantation; 2004 Aug 15; 78(3):426-33. PubMed ID: 15316372
    [Abstract] [Full Text] [Related]

  • 8. C4d positivity is often associated with acute cellular rejection in renal transplant biopsies following Campath-1H (Alemtuzumab) induction.
    Zhang PL, Malek SK, Blasick TM, Pennington JR, Masker KK, Lun M, Potdar S.
    Ann Clin Lab Sci; 2007 Aug 15; 37(2):121-6. PubMed ID: 17522366
    [Abstract] [Full Text] [Related]

  • 9. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M, Song SH, Kim JM, Kwon CH, Joh JW, Lee SK, Kim SJ.
    Transplant Proc; 2011 Aug 15; 43(6):2365-78. PubMed ID: 21839271
    [Abstract] [Full Text] [Related]

  • 10. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).
    Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL, Cendales LK, Tadaki DK, Harlan DM, Swanson SJ.
    Transplantation; 2003 Jul 15; 76(1):120-9. PubMed ID: 12865797
    [Abstract] [Full Text] [Related]

  • 11. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
    Trzonkowski P, Zilvetti M, Friend P, Wood KJ.
    Transplantation; 2006 Nov 27; 82(10):1342-51. PubMed ID: 17130784
    [Abstract] [Full Text] [Related]

  • 12. Early and late humoral rejection: a clinicopathologic entity in two times.
    Péfaur J, Díaz P, Panace R, Salinas P, Fiabane A, Quinteros N, Chea R, Naranjo E, Wurgaft A, Beltran E, Elgueta S, Wegmann ME, Gajardo JG, Contreras L.
    Transplant Proc; 2008 Nov 27; 40(9):3229-36. PubMed ID: 19010241
    [Abstract] [Full Text] [Related]

  • 13. Monocyte-mediated acute renal rejection after combined treatment with preoperative Campath-1H (alemtuzumab) and postoperative immunosuppression.
    Zhang PL, Malek SK, Prichard JW, Lin F, Yahya TM, Schwartzman MS, Latsha RP, Skaletsky M, Norfolk ER, Brown RE, Hartle JE, Potdar S.
    Ann Clin Lab Sci; 2004 Nov 27; 34(2):209-13. PubMed ID: 15228236
    [Abstract] [Full Text] [Related]

  • 14. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.
    Knechtle SJ, Pirsch JD, H Fechner J, Becker BN, Friedl A, Colvin RB, Lebeck LK, Chin LT, Becker YT, Odorico JS, D'Alessandro AM, Kalayoglu M, Hamawy MM, Hu H, Bloom DD, Sollinger HW.
    Am J Transplant; 2003 Jun 27; 3(6):722-30. PubMed ID: 12780564
    [Abstract] [Full Text] [Related]

  • 15. Reversal of acute cellular rejection after renal transplantation with Campath-1H.
    Basu A, Ramkumar M, Tan HP, Khan A, McCauley J, Marcos A, Fung JJ, Starzl TE, Shapiro R.
    Transplant Proc; 2005 Mar 27; 37(2):923-6. PubMed ID: 15848576
    [Abstract] [Full Text] [Related]

  • 16. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J, Xue W, Qing X, Jing X, Hou J, Tian X, Guo Q, He X, Cai J.
    Clin Transpl; 2014 Mar 27; ():223-30. PubMed ID: 26281149
    [Abstract] [Full Text] [Related]

  • 17. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
    Lawrence C, Willicombe M, Brookes PA, Santos-Nunez E, Bajaj R, Cook T, Roufosse C, Taube D, Warrens AN.
    Transplantation; 2013 Jan 27; 95(2):341-6. PubMed ID: 23197178
    [Abstract] [Full Text] [Related]

  • 18. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
    Klein K, Süsal C, Schäfer SM, Becker LE, Beimler J, Schwenger V, Zeier M, Schemmer P, Macher-Goeppinger S, Scherer S, Opelz G, Morath C.
    Atheroscler Suppl; 2013 Jan 27; 14(1):199-202. PubMed ID: 23357165
    [Abstract] [Full Text] [Related]

  • 19. Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy.
    Willicombe M, Brookes P, Santos-Nunez E, Galliford J, Ballow A, Mclean A, Roufosse C, Cook HT, Dorling A, Warrens AN, Cairns T, Taube D.
    Am J Transplant; 2011 Mar 27; 11(3):470-7. PubMed ID: 21299828
    [Abstract] [Full Text] [Related]

  • 20. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation.
    Lederer SR, Friedrich N, Banas B, Welser G, Albert ED, Sitter T.
    Clin Transplant; 2005 Apr 27; 19(2):168-74. PubMed ID: 15740551
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.